The cardiac mitochondrion: Nexus of stress

Annual Review of Physiology

Volumn 72, Issue , 2009, Pages 61-80

  Baines, Christopher P ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Apoptosis; Bcl2 proteins; Cardiac disease; Mitochondria; Mitochondrial permeability transition; Mitochondrial potassium channels; Uncoupling proteins

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ALDEHYDE DEHYDROGENASE ISOENZYME 2; APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; BH3 PROTEIN; CASPASE 3; CONNEXIN 43; CYCLOPHILIN D; CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; CYTOCHROME C; ENDONUCLEASE G; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NIX PROTEIN; PORIN; PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BNIP3; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; SANGLEFEHRIN A; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN; UNINDEXED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; APOPTOSIS REGULATORY PROTEIN; POTASSIUM CHANNEL;

CARDIOMYOPATHY; CELL DEATH; HEART DISEASE; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; APOPTOSIS; DRUG EFFECT; METABOLISM; PERMEABILITY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; MITOCHONDRIA, HEART; PERMEABILITY; PORINS; POTASSIUM CHANNELS; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 77951920370     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021909-135929     Document Type: Review

References (147)

1. Kroemer G, Galluzzi L, Brenner C. 2007. Mitochondrial permeabilization in cell death. Physiol. Rev. 87:99-163
2. Crow MT, Mani K, Nam YJ, Kitsis RN. 2004. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ. Res. 95:957-970
3. Gross A, McDonnell JM, Korsmeyer SJ. 1999. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899-1911
4. Gustafsson AB, Gottlieb RA. 2008. Heart mitochondria: gates of life and death. Cardiovasc. Res. 77:334-343
5. Sharpe JC, Arnoult D, Youle RJ. 2004. Control of mitochondrial permeability by Bcl-2 family members. Biochim. Biophys. Acta 1644:107-113
6. Regula KM, Kirshenbaum LA. 2005. Apoptosis of ventricular myocytes: a means to an end. J. Mol. Cell. Cardiol. 38:3-13
7. Di Lisa F, Canton M, Menab̀o R, Kaludercic N, Bernardi P. 2007. Mitochondria and cardioprotection. Heart Fail. Rev. 12:249-260
8. Halestrap AP, Clarke SJ, Javadov SA. 2004. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc. Res. 61:372-385
9. Murphy E, Steenbergen C. 2008. Mechanisms underlying acute protection from cardiac ischemiareperfusion injury. Physiol. Rev. 88:581-609
10. Weiss JN, Korge P, Honda HM, Ping P. 2003. Role of the mitochondrial permeability transition in myocardial disease. Circ. Res. 93:292-301
11. Halestrap A. 2005. Biochemistry: a pore way to die. Nature 434:578-579
12. Forte M, Bernardi P. 2005. Genetic dissection of the permeability transition pore. J. Bioenerg. Biomembr. 37:121-128
13. Yue TL, Wang C, Romanic AM, Kikly K, Keller P, et al. 1998. Staurosporine-induced apoptosis in cardiomyocytes: a potential role of caspase-3. J. Mol. Cell. Cardiol. 30:495-507
14. Hayakawa Y, Chandra M, Miao W, Shirani J, Brown JH, et al. 2003. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Gαq transgenic mice. Circulation 108:3036-3041
15. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, et al. 2003. A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Investig. 111:1497-1504
16. Wu S, Ko YS,Teng MS,Ko YL, Hsu LA, et al. 2002. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J. Mol. Cell. Cardiol. 34:1595-1607
17. Holly TA, Drincic A, Byun Y, Nakamura S, Harris K, et al. 1999. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J. Mol. Cell. Cardiol. 31:1709-1715
18. Chua CC, Gao J, Ho YS, Xiong Y, Xu X, et al. 2007. Overexpression of IAP-2 attenuates apoptosis and protects against myocardial ischemia/reperfusion injury in transgenic mice. Biochim. Biophys. Acta 1773:577-583
19. Vandenabeele P, Vanden Berghe T, Festjens N. 2006. Caspase inhibitors promote alternative cell death pathways. Sci. STKE 2006:pe44
20. Brady NR, Hamacher-Brady A, Gottlieb RA. 2006. Proapoptotic BCL-2 family members and mitochondrial dysfunction during ischemia/reperfusion injury, a study employing cardiac HL-1 cells and GFP biosensors. Biochim. Biophys. Acta 1757:667-678
21. Capano M, Crompton M. 2006. Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem. J. 395:57-64
22. An J, Li P, Li J, Dietz R, Donath S. 2009. ARC is a critical cardiomyocyte survival switch in doxorubicin cardiotoxicity. J. Mol. Med. 87:401-410
23. Gustafsson AB, Tsai JG, Logue SE, Crow MT, Gottlieb RA. 2004. Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation. J. Biol. Chem. 279:21233-21238
24. Hochhauser E, Cheporko Y, Yasovich N, Pinchas L, Offen D, et al. 2007. Bax deficiency reduces infarct size and improves long-term function after myocardial infarction. Cell. Biochem. Biophys. 47:11-20
25. Latif N, Khan MA, Birks E, O'Farrell A, Westbrook J, Dunn MJ, Yacoub MH. 2000. Upregulation of the Bcl-2 family of proteins in end stage heart failure. J. Am. Coll. Cardiol. 35:1769-1777
26. Chen G, Ray R, Dubik D, Shi L, Cizeau J, et al. 1997. The E1B 19K/Bcl-2-binding protein Nip3 is a dimeric mitochondrial protein that activates apoptosis. J. Exp. Med. 186:1975-1983
27. Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, et al. 2000. BNIP3 heterodimerizes with Bcl-2/Bcl-XL and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J. Biol. Chem. 275:1439-1448
28. Regula KM, Ens K, Kirshenbaum LA. 2002. Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ. Res. 91:226-231
29. Kubli DA, Ycaza JE, Gustafsson AB. 2007. Bnip3 mediates mitochondrial dysfunction and cell death through Bax and Bak. Biochem. J. 405:407-415
30. Kubasiak LA, Hernandez OM, Bishopric NH,Webster KA. 2002. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc. Natl. Acad. Sci. USA 99:12825-12830
31. Hamacher-Brady A, Brady NR, Logue SE, Sayen MR, Jinno M, et al. 2007. Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy. Cell Death Differ. 14:146-157
32. Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, et al. 2007. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J. Clin. Investig. 117:2825-2833
33. Gálvez AS, Brunskill EW, Marreez Y, Benner BJ, Regula KM, et al. 2006. Distinct pathways regulate proapoptotic Nix and BNip3 in cardiac stress. J. Biol. Chem. 281:1442-1448
34. Yussman MG, Toyokawa T, Odley A, Lynch RA,Wu G, et al. 2002. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat. Med. 8:725-730
35. Diwan A,Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW. 2008. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation 117:396-404
36. Toth A, Jeffers JR, Nickson P, Min JY, Morgan JP, et al. 2006. Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol. 291:H52-60
37. Nithipongvanitch R, Ittarat W, Velez JM, Zhao R, St Clair DK, Oberley TD. 2007. Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome following acute adriamycin treatment. J. Histochem. Cytochem. 55:629-639
38. Scarabelli TM, Stephanou A, Pasini E, Comini L, Raddino R, et al. 2002. Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury. Circ. Res. 90:745-748
39. Lien YC, Lin SM, Nithipongvanitch R, Oberley TD, Noel T, et al. 2006. Tumor necrosis factor receptor deficiency exacerbated Adriamycin-induced cardiomyocytes apoptosis: an insight into the Fas connection. Mol. Cancer Ther. 5:261-269
40. Maulik N, Engelman RM, Rousou JA, Flack JE 3rd, Deaton D, Das DK. 1999. Ischemic preconditioning reduces apoptosis by upregulating antideath gene Bcl-2. Circulation 100:II369-75
41. Chen X, Chen Y, Bi Y, Fu N, Shan C, et al. 2007. Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Cardiovasc. Drugs Ther. 21:367-374
42. Zhao ZQ, Nakamura M,Wang NP,Wilcox JN, Shearer S, et al. 2000. Reperfusion induces myocardial apoptotic cell death. Cardiovasc. Res. 45:651-660
43. Reeve JL, Szegezdi E, Logue SE, Chonghaile TN, O'Brien T, et al. 2007. Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL. J. Cell Mol. Med. 11:509-520
44. Lankford AR, Byford AM, Ashton KJ, French BA, Lee JK, et al. 2002. Gene expression profile of mouse myocardium with transgenic overexpression of A1 adenosine receptors. Physiol. Genomics 11:81-89
45. Imahashi K, Schneider MD, Steenbergen C, Murphy E. 2004. Transgenic expression of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during ischemia, and reduces ischemia/reperfusion injury. Circ. Res. 95:734-741
46. Tanaka M, Nakae S, Terry RD, Mokhtari GK, Gunawan F, et al. 2004. Cardiomyocyte-specific Bcl-2 overexpression attenuates ischemia-reperfusion injury, immune response during acute rejection, and graft coronary artery disease. Blood 104:3789-3796
47. Chen Z, Chua CC,HoYS,HamdyRC, Chua BH. 2001. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am. J. Physiol. Heart Circ. Physiol. 280:H2313-20
48. Weisleder N, Taffet GE, Capetanaki Y. 2004. Bcl-2 overexpression corrects mitochondrial defects and ameliorates inherited desmin null cardiomyopathy. Proc. Natl. Acad. Sci. USA 101:769-774
49. Huang J, Ito Y, Morikawa M, Uchida H, Kobune M, et al. 2003. Bcl-xL gene transfer protects the heart against ischemia/reperfusion injury. Biochem. Biophys. Res. Commun. 311:64-70
50. Oakes SA, Opferman JT, Pozzan T, Korsmeyer SJ, Scorrano L. 2003. Regulation of endoplasmic reticulum Ca2+ dynamics by proapoptotic BCL-2 family members. Biochem. Pharmacol. 66:1335-1340
51. Nakayama N, Chen X, Baines CP, Klevitsky R, Zhang H, et al. 2007.Ca2+-and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J. Clin. Investig. 117:2431-2444
52. Koseki T, Inohara N, Chen S, Nuñez G. 1998. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc. Natl. Acad. Sci. USA 95:5156-5160
53. Nam YJ, Mani K, Ashton AW, Peng CF, Krishnamurthy B, et al. 2004. Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. Mol. Cell 15:901-912
54. Foo RS, Nam YJ, Ostreicher MJ,Metzl MD,Whelan RS, et al. 2007. Regulation of p53 tetramerization and nuclear export by ARC. Proc. Natl. Acad. Sci. USA 104:20826-20831
55. Foo RS, Chan LK, Kitsis RN, Bennett MR. 2007. Ubiquitination and degradation of the antiapoptotic protein ARC by MDM2. J. Biol. Chem. 282:5529-5535
56. Donath S, Li P, Willenbockel C, Al-Saadi N, Gross V, et al. 2006. Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation 113:1203-1212
57. Pyo JO, Nah J, Kim HJ, Chang JW, Song YW, et al. 2008. Protection of cardiomyocytes from ischemic/hypoxic cell death via Drbp1 and pMe2GlyDH in cardio-specific ARC transgenic mice. J. Biol. Chem. 283:30707-30714
58. Chatterjee S, Bish LT, Jayasankar V, Stewart AS, Woo YJ, et al. 2003. Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain. J. Thorac. Cardiovasc. Surg. 125:1461-1469
59. Hunter DR, Haworth RA, Southard JH. 1976. Relationship between configuration, function, and permeability in calcium-treated mitochondria. J. Biol. Chem. 251:5069-5077
60. Vyssokikh MY, Katz A, Rueck A, Wuensch C, Dorner A, et al. 2001. Adenine nucleotide translocator isoforms 1 and 2 are differently distributed in the mitochondrial inner membrane and have distinct affinities to cyclophilin D. Biochem J. 358:349-358
61. Crompton M, Virji S, Ward JM. 1998. Cyclophilin-D binds strongly to complexes of the voltagedependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Eur. J. Biochem. 258:729-735
62. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, et al. 2005. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434:658-662
63. Clarke SJ, McStay GP, Halestrap AP. 2002. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J. Biol. Chem. 277:34793-34799
64. Di Lisa F, Menab̀o R, Canton M, Barile M, Bernardi P. 2001. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J. Biol. Chem. 276:2571-2575
65. Hausenloy DJ, Duchen MR, Yellon DM. 2003. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc. Res. 60:617-625
66. Haworth RA, Hunter DR. 2000. Control of the mitochondrial permeability transition pore by highaffinity ADP binding at the ADP/ATP translocase in permeabilized mitochondria. J. Bioenerg. Biomembr. 32:91-96
67. Blachly-Dyson E, Forte M. 2001. VDAC channels. IUBMB Life 52:113-118
68. Rostovtseva TK, Tan W, Colombini M. 2005. On the role of VDAC in apoptosis: fact and fiction. J. Bioenerg. Biomembr. 37:129-142
69. Wu S, Sampson MJ, Decker WK, Craigen WJ. 1999. Each mammalian mitochondrial outer membrane porin protein is dispensable: effects on cellular respiration. Biochim. Biophys. Acta 1452:68-78
70. Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, Tsujimoto Y. 2001. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J. Cell Biol. 152:237-250
71. Zheng Y, Shi Y,Tian C, Jiang C, Jin H, et al. 2004. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 23:1239-1247
72. Cesura AM, Pinard E, Schubenel R, Goetschy V, Friedlein A, et al. 2003. The voltage-dependent anion channel is the target for a new class of inhibitors of the mitochondrial permeability transition pore. J. Biol. Chem. 278:49812-49818
73. Woodfield K, Ruck A, Brdiczka D, Halestrap AP. 1998. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem. J. 336:287-290
74. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. 2007. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat. Cell Biol. 9:550-555
75. Fiore C, Trézéguet V, Le Saux A, Roux P, Schwimmer C, et al. 1998. The mitochondrial ADP/ATP carrier: structural, physiological and pathological aspects. Biochimie 80:137-150
76. Palmieri F. 2004. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflüg. Arch. 447:689-709
77. Halestrap AP, Davidson AM. 1990. Inhibition of Ca2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem. J. 268:153-160
78. Bauer MK, Schubert A, Rocks O, Grimm S. 1999. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. J. Cell Biol. 147:1493-1502
79. Zamora M, Granell M, Mampel T, Vinas O. 2004. Adenine nucleotide translocase 3 (ANT3) overexpression induces apoptosis in cultured cells. FEBS Lett. 563:155-160
80. Jang JY, Choi Y, Jeon YK, Aung KC, Kim CW. 2008. Over-expression of adenine nucleotide translocase 1 (ANT1) induces apoptosis and tumor regression in vivo. BMC Cancer 8:160
81. Baines CP, Molkentin JD. 2009. Adenine nucleotide translocase-1 induces cardiomyocyte death through upregulation of the proapoptotic protein Bax. J. Mol. Cell. Cardiol. 46:969-977
82. Kokoszka J, Waymire KG, Levy SE, Sligh JE, Cai J, et al. 2004. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427:461-465
83. Connern CP, Halestrap AP. 1992. Purification and N-terminal sequencing of peptidyl-prolyl cis-transisomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. Biochem. J. 284:381-385
84. Andreeva L, Tanveer A, Crompton M. 1995. Evidence for the involvement of a membrane-associated cyclosporin-A-binding protein in the Ca2+-activated inner membrane pore of heart mitochondria. Eur. J. Biochem. 230:1125-1132
85. Reutenauer J, DorchiesOM,Patthey-Vuadens O,Vuagniaux G, Ruegg UT. 2008. Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br. J. Pharmacol. 155:574-584
86. Gomez L, Thibault H, Gharib A, Dumont JM, Vuagniaux G, et al. 2007. Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am. J. Physiol. 293:H1654-61
87. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. 2005. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J. Biol. Chem. 280:18558-18561
88. Nakagawa T, Shimizu S,Watanabe T, Yamaguchi O, Otsu K, et al. 2005. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434:652-658
89. Schinzel A, Takeuchi O, Huang Z, Fisher JK, Zhou Z, et al. 2005. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 102:12005-12010
90. Leung AW, Varanyuwatana P, Halestrap AP. 2008. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J. Biol. Chem. 283:26312-26323
91. Alcalá S, Klee M, Fernández J, Fleischer A, Pimentel-Muiños FX. 2008. A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release. Oncogene 27:44-54
92. Griffiths EJ, Halestrap AP. 1993. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J. Mol. Cell. Cardiol. 25:1461-1469
93. Duchen MR, McGuinness O, Brown LA, Crompton M. 1993. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc. Res. 27:1790-1794
94. Kato M, Akao M, Matsumoto-Ida M, Makiyama T, Iguchi M, et al. 2009. The targeting of cyclophilin D by RNAi as a novel cardioprotective therapy: evidence from two-photon imaging. Cardiovasc. Res. 83:335-344
95. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. 2007. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc. Res. 75:530-535
96. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, et al. 2008. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat. Med. 14:442-447
97. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, et al. 2006. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12:908-916
98. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. 2001. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61:771-777
99. Matas J, Tien Sing Young N, Bourcier-Lucas C, Ascah A, Marcil M, et al. 2009. Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy. J. Mol. Cell. Cardiol. 46:420-430
100. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, et al. 2008. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med. 359:473-481
101. Szewczyk A, Jarmuszkiewicz W, Kunz WS. 2009. Mitochondrial potassium channels. IUBMB Life 61:134-143
102. Garlid KD, Paucek P. 2001. The mitochondrial potassium cycle. IUBMB Life 52:153-158
103. Inoue I, Nagase H, Kishi K, Higuti T. 1991. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature 352:244-247
104. Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, et al. 1997. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ. Res. 81:1072-1082
105. Liu Y, Sato T, O'Rourke B, Marban E. 1998. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 97:2463-2469
106. Ardehali H, O'Rourke B. 2005. Mitochondrial K(ATP) channels in cell survival and death. J. Mol. Cell. Cardiol. 39:7-16
107. Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD. 2006. The mechanism by which the mitochondrial ATP-sensitive K+ channel opening andH2O2 inhibit the mitochondrial permeability transition. J. Biol. Chem. 281:20801-20808
108. Korge P, Honda HM, Weiss JN. 2002. Protection of cardiac mitochondria by diazoxide and protein kinase C: implications for ischemic preconditioning. Proc. Natl. Acad. Sci. USA 99:3312-3317
109. Murata M, Akao M, O'Rourke B, Marbán E. 2001. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca2+ overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ. Res. 89:891-898
110. Holmuhamedov EL,Wang L,Terzic A. 1999. ATP-sensitive K+ channel openers prevent Ca2+ overload in rat cardiac mitochondria. J. Physiol. 519:347-360
111. Garlid KD. 2000. Opening mitochondrial K(ATP) in the heart-what happens, and what does not happen. Basic Res. Cardiol. 95:275-279
112. Costa AD, Garlid KD. 2008. Intramitochondrial signaling: interactions among mitoKATP, PKCε, ROS, and MPT. Am. J. Physiol. Heart Circ. Physiol. 295:H874-82
113. Baines CP, Song CX, Zheng YT,Wang GW, Zhang J, et al. 2003. Protein kinase Cε interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ. Res. 92:873-880
114. Paucek P, Mironova G, Mahdi F, Beavis AD, Woldegiorgis G, Garlid KD. 1992. Reconstitution and partial purification of the glibenclamide-sensitive, ATP-dependent K+ channel from rat liver and beef heart mitochondria. J. Biol. Chem. 267:26062-26069
115. Singh H, Hudman D, Lawrence CL, Rainbow RD, Lodwick D, Norman RI. 2003. Distribution of Kir6.0 and SUR2 ATP-sensitive potassium channel subunits in isolated ventricular myocytes. J. Mol. Cell. Cardiol. 35:445-459
116. Lacza Z, Snipes JA, Kis B, SzaboC, Grover G, BusijaDW.2003. Investigation of the subunit composition and the pharmacology of the mitochondrial ATP-dependent K+ channel in the brain. Brain Res. 994:27-36
117. Seharaseyon J, Ohler A, Sasaki N, Fraser H, Sato T, et al. 2000. Molecular composition of mitochondrial ATP-sensitive potassium channels probed by viral Kir gene transfer. J. Mol. Cell. Cardiol. 32:1923-1930
118. Ardehali H, Chen Z, Ko Y, Mejá-Alvarez R, Marbán E. 2004. Multiprotein complex containing succinate dehydrogenase confers mitochondrial ATP-sensitive K+ channel activity. Proc. Natl. Acad. Sci. USA 101:11880-11885
119. Siemen D, Loupatatzis C, Borecky J, Gulbins E, Lang F. 1999. Ca2+-activated K channel of the BKtype in the inner mitochondrial membrane of a human glioma cell line. Biochem. Biophys. Res. Commun. 257:549-554
120. Xu W, Liu Y, Wang S, McDonald T, Van Eyk JE, Sidor A, O'Rourke B. 2002. Cytoprotective role of Ca2+-activated K+ channels in the cardiac inner mitochondrial membrane. Science 298:1029-1033
121. Debska G, Kicinska A, Dobrucki J, Dworakowska B, Nurowska E, et al. 2003. Large-conductance K+ channel openers NS1619 and NS004 as inhibitors of mitochondrial function in glioma cells. Biochem. Pharmacol. 65:1827-1834
122. Sato T, Saito T, Saegusa N, Nakaya H. 2005. Mitochondrial Ca2+-activated K+ channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 111:198-203
123. Ohya S, Kuwata Y, Sakamoto K, Muraki K, Imaizumi Y. 2005. Cardioprotective effects of estradiol include the activation of large-conductance Ca2+-activated K+ channels in cardiac mitochondria. Am. J. Physiol. Heart Circ. Physiol. 289:H1635-42
124. Heinen A, Aldakkak M, Stowe DF, Rhodes SS, Riess ML, et al. 2007. Reverse electron flow-induced ROS production is attenuated by activation of mitochondrial Ca2+-sensitive K+ channels. Am. J. Physiol. Heart Circ. Physiol. 293:H1400-7
125. Cheng Y, Gu XQ, Bednarczyk P, Wiedemann FR, Haddad GG, Siemen D. 2008. Hypoxia increases activity of the BK-channel in the inner mitochondrial membrane and reduces activity of the permeability transition pore. Cell. Physiol. Biochem. 22:127-136
126. Kang SH, Park WS, Kim N, Youm JB,Warda M, et al. 2007. Mitochondrial Ca2+-activated K+ channels more efficiently reduce mitochondrial Ca2+ overload in rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 293:H307-13
127. Szab ̀o I, Bock J, Jekle A, Soddemann M, Adams C, et al. 2005. A novel potassium channel in lymphocyte mitochondria. J. Biol. Chem. 280:12790-12798
128. Szabó I, Bock J, Grassmé H, Soddemann M, Wilker B, et al. 2008. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proc. Natl. Acad. Sci. USA 105:14861-14866
129. Sack MN. 2006. Mitochondrial depolarization and the role of uncoupling proteins in ischemia tolerance. Cardiovasc. Res. 72:210-219
130. Wallace DC. 2001. Mouse models for mitochondrial disease. Am. J. Med. Genet. 106:71-93
131. McLeod CJ, Aziz A, Hoyt RF Jr, McCoy JP Jr, Sack MN. 2005. Uncoupling proteins 2 and 3 function in concert to augment tolerance to cardiac ischemia. J. Biol. Chem. 280:33470-33476
132. Guo P, Mizushige K, Noma T, Murakami K, Namba T, et al. 2005. Association of uncoupling protein-2 expression with increased reactive oxygen species in residual myocardium of the enlarged left ventricle after myocardial infarction. Heart Vessels 20:61-65
133. Zungu M, Alcolea MP, García-Palmer FJ, Young ME, Essop MF. 2007. Genomic modulation of mitochondrial respiratory genes in the hypertrophied heart reflects adaptive changes in mitochondrial and contractile function. Am. J. Physiol. Heart Circ. Physiol. 293:H2819-25
134. Teshima Y, Akao M, Jones SP, Marbán E. 2003. Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. Circ. Res. 93:192-200
135. Bodyak N, Rigor DL, Chen YS, Han Y, Bisping E, et al. 2007. Uncoupling protein 2 modulates cell viability in adult rat cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 293:H829-35
136. Hoerter J, Gonzalez-Barroso MD, Couplan E, Mateo P, Gelly C, et al. 2004. Mitochondrial uncoupling protein 1 expressed in the heart of transgenic mice protects against ischemic-reperfusion damage. Circulation 110:528-533
137. Schwanke U, Konietzka I, Duschin A, Li X, Schulz R, Heusch G. 2002. No ischemic preconditioning in heterozygous connexin43-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 283:H1740-42
138. Heinzel FR, Luo Y, Li X, Boengler K, Buechert A, et al. 2005. Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. Circ. Res. 97:583-586
139. Boengler K, Stahlhofen S, van de Sand A, Gres P, Ruiz-Meana M, et al. 2009. Presence of connexin 43 in subsarcolemmal, but not in interfibrillar cardiomyocyte mitochondria. Basic Res. Cardiol. 104:141-147
140. Rodriguez-Sinovas A, Boengler K, Cabestrero A, Gres P, Morente M, et al. 2006. Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection. Circ. Res. 99:93-101
141. Boengler K, Ruiz-Meana M, Miro-Casas E, Cabestrero A, Rodriguez-Sinovas A, et al. 2006. Connexin 43 controls mitochondrial respiration. Circulation 114:II-243
142. Ruiz-Meana M, Rodríguez-Sinovas A, Cabestrero A, Boengler K, Heusch G, Garcia-Dorado D. 2008. Mitochondrial connexin43 as a new player in the pathophysiology of myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 77:325-333
143. Yoshida A, Rzhetsky A, Hsu LC, Chang C. 1998. Human aldehyde dehydrogenase gene family. Eur. J. Biochem. 251:549-557
144. Wenzel P, Schuhmacher S, Kienhöfer J, Müller J, Hortmann M, et al. 2008. Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc. Res. 80:280-289
145. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. 2008. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321:1493-1495
146. Churchill EN, Disatnik MH, Mochly-Rosen D. 2009. Time-dependent and ethanol-induced cardiac protection from ischemia mediated by mitochondrial translocation of εPKC and activation of aldehyde dehydrogenase 2. J. Mol. Cell. Cardiol. 46:278-284
147. Eaton P, Li JM, Hearse DJ, Shattock MJ. 1999. Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am. J. Physiol. 276:H935-43